Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07254208
Enrolling by invitation Observational

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

NCT07254208 · tracked via the Priya Life Science USA tracker
Sponsor
Precision BioSciences, Inc
Phase
Observational
Started
2025-12-25
Last updated
2026-04-22

Condition(s) studied

Chronic HBV Infection

Investigational drug(s) / intervention(s)

PBGENE-HBV →

PBGENE-HBV: PBGENE-HBV is the investigational product administered in the parent study. This LTFU study is non-interventional; no investigational product given.

Study summary

Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.

Eligibility

Sex
ALL
Min age
19 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Participant has received at least 1 dose of PBGENE-HBV investigational product in a prior clinical study 2. Participant, or their legally authorized representative, has provided signed informed consent. Exclusion Criteria: * N/A

Primary outcome measure(s)

  • Safety to assess frequency, severity, and outcome of delayed adverse events — 15 years
    Delayed adverse events

Trial sites (4)

FacilityCityRegionStatus
Massachusetts General Hospital/Harvard University Boston Massachusetts
Queen Mary Hospital, University of Hong Kong Hong Kong Hong Kong
ICS ARENSIA Exploratory Medicine SRL Chisinau Moldova
New Zealand Clinical Research Auckland New Zealand

More Precision BioSciences, Inc. trials in the USA

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) Recruiting
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07254208 on ClinicalTrials.gov ↗ ← All trials in the USA